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A B S T R A C T
From a screening study of various potential inhibitors for cholinesterases (ChEs), compound (rac)-1 (4-((3-hydroxy-2-oxo-3-phenylindolin-1-yl) methyl) piperidin-1-
ium chloride) showed an IC50 of 18 μM for butyrylcholinesterase (BuChE). Herein we present a toxicological and pharmacological evaluation of (rac)-1 to determine
its potential for use as an alternative ChE inhibitor for the treatment of Alzheimer’s disease. The strategy adopted included in vivo and ex vivo studies with mouse
models, Molecular Modelling and Saturation Transfer Difference (STD) NMR studies.
Preliminary molecular docking studies were conducted with both (R) and (S)-1 with acetylcholinesterase (AChE) and BuChE, prior to advancing to the mouse
model, and indeed favorable interactions were observed, with (R)-1 showing the best binding with AChE and (S)-1 with BuChE. STD-NMR studies were used to
successfully validate these results. Toxicological studies were also conducted using the Artemia salina model, with donepezil as reference. It was found that in the in
vivo mouse studies that (rac)-1 presented a slightly better inhibition of AChE (0.096 µmol.min−1.mg−1) than donepezil (0.112 µmol.min−1.mg−1) and the same level
of inhibition for BuChE as donepezil (0.014 µmol.min−1.mg−1).
1. Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative
disease and the most prevalent cause of dementia among the elderly.1,2
This irreversible neurological disorder is characterized by memory and
cognitive impairment, behavioral and learning deficits.3,4 Neuro-
pathologically, AD is portrayed by the presence of amyloid β (Aβ)
plaques and neurofibrillary tangles (NFT) of a phosphorylated form of
protein tau. The formation of Aβ plaques and NFTs leads to neurode-
generation and loss of cholinergic neurons in the basal forebrain with
consequent reduction of acetylcholine (ACh) levels in the hippocampus
and cortex of the brain.5 Both acetylcholinesterase (AChE) and butyr-
ylcholinesterase (BuChE) degrade ACh, this is more prevalent for
BuChE in the latter stages of the disease. In order to increase ACh levels,
the use of reversible inhibitors of the enzyme acetylcholinesterase
(AChE) and butyrylcholinesterase (BuChE) has been one of the prime
strategies for controlling the symptoms of AD.6,7 There is no cure for
this disease. Nowadays, only three drugs are commercially available as
AChE inhibitors for the treatment of AD: galantamine, rivastigmine and
donepezil (Fig. 1) and which have different draw-backs.8 Given this
situation, it is imperative that new and less expensive AChE inhibitors
become available for AD treatment.
The hydroxyoxindole scaffold is present in a number of molecules
that exhibit diverse pharmacological profiles, that includes anti-cancer,
anti-HIV, antioxidant, antibacterial, antidiabetic, AChE/BuChE inhibi-
tion, kinase inhibition, vasopressin antagonism, progesterone antag-
onism, anti-leishmanial, β3 adrenergic receptor antagonism, analgesic,
spermicidal, phosphatase inhibition, neuroprotection, and N-methyl-D-
aspartate (NMDA) blocker activities.9
We have previously reported the design and synthesis of a new fa-
mily of tertiary 3-hydroxy- and 3-alkoxyoxindole derivatives which
presented good AChE and BuChE inhibitory activities.10 Some of the
key hits ((rac)-1 to (rac)-4) that were identified are shown in Fig. 2 with
their IC50 values. Our interest then moved to evaluating these com-
pounds in an animal model, and thus the issue of bioavailability was
critical. We found that (rac)-1 (4-((3-hydroxy-2-oxo-3-phenylindolin-1-
yl) methyl) piperidin-1-ium chloride) (Fig. 2) gave promising inhibition
of BuChE (18 μM) (under incubation conditions). In addition, only after
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conclusion of our bioassays did we develop a robust asymmetric route
to (rac)-410 which eventually can also be used to access both en-
antiomers of (rac)-1 for further pre-clinical pharmacological evalua-
tions. Due to its favorable solubility and physico-chemical properties
(see discussion below), (rac)-1 was chosen for further pharmacological
evaluation. Herein we present a toxicological and pharmacological
evaluation of (rac)- 1, including in vivo and ex vivo studies with mouse
models, Molecular Modelling and Saturation Transfer Difference (STD)
NMR studies.
2. Results and discussion
2.1. Synthesis of (rac)-1
Compound (rac)-1 was synthesized following our previously pub-
lished synthetic methodology.10 The synthetic procedure comprises a
Phenyl-Grignard Nucleophilic Addition at the 3-carbonyl group of the
isatin substrate and subsequent microwave assisted N-alkylation at
position 1 with 4-(N-Boc-piperidinyl)-methylenyl-methylsulfonate. The
hydrochloride salt was obtained by deprotection under acidic condi-
tions.
2.2. Docking analysis with cholinesterases
Some important physicochemical parameters of relevance for drug
design: are MW (Molecular Weight including implicit hydrogens), TPSA
(Polar surface area (Å2) (calculated using group contributions to ap-
proximate the polar surface area from connection table information
only, parametrization of Ertl et al.,11) solubility (logS, calculated from
an atom contribution linear atom type model12) and lipophilicity (logP,
calculated as the log of the octanol/water partition coefficient, this
property is calculated from a ∼100 parameter linear atom type model
on 1827 molecules13) were calculated using MOE 2018 descriptors
option.14 These properties were calculated for compounds (rac)-1 –
(rac)-4 (Table 1).
All the analyzed compounds showed low molecular weights, re-
vealing an interesting potential for derivatization. Both (rac)-1 and
(rac)-3 were the lower MW compounds studied. Also, calculations of
TPSA (topological polar surface area), all below 60 Å2, suggest that
these compounds should be almost completely absorbed.
Since lipophilicity is identified as an important descriptor for CNS
penetration we were pleased to observe that the calculated logP value
for (rac)-1 was the lowest for all the tested compounds. In fact, Hansch
and Leo have proposed that highly lipophilic molecules are partitioned
within the lipid interior of the membrane, and thus retained there.15
For several classes of CNS active substances, Hansch and Leo found that
blood-brain barrier penetration is optimal when the logP values are in
the range of 1.5–2.7, with the mean value of 2.1, a value in the same
range as that calculated for (rac)-1. As a comparison, the mean value for
ClogP for some of the marketed CNS drugs is 2.5.
Solubility of a drug candidate is an important property as it reflects
the bioavailability of the compound. Dose formulation is a problem for
compounds showing poor solubility. We calculated logS for the four
compounds and we found that (rac)-1 is the compound with a greatest
logS (less negative), i.e. −3.54. > 80% of the drugs on the market have
a (estimated) logS value greater than −4.
Fig. 1. Current Food and Drug Administration (FDA) – approved drugs for AD (cholinesterase inhibitors).
Fig. 2. (rac)-1 (4-((3-Hydroxy-2-oxo-3-phenylindolin-1-yl) methyl) piperidin-1-ium chloride) and the analogous compounds (rac)-2, (rac)-3 and (rac)-4 previously
identified as ChE inhibitors.10 Results for (rac)-1 and (rac)-2 were obtained under incubation conditions.
Table 1
Physicochemical properties. Molecular descriptors calculated by MOE
2018.0101, MW (Molecular Weight), TPSA (Polar surface area (Å2)), logS (log
of the aqueous solubility mol/L) and logP (log of the octanol/water partition
coefficient).
Compound MW TPSA logS logP
(rac)-1 323.4 57.15 −3.54 2.79
(rac)-2 413.5 44.98 −5.44 4.85
(rac)-3 315.4 40.54 −4.94 4.16
(rac)-4 349.8 40.54 −5.67 4.78
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These results clearly indicated that of the 4 compounds described
(rac)-1 was the best candidate for animal model studies.
2.2.1. Ligand interactions with acetylcholinesterase
Kinetic studies using (rac)-1 and eeAChE (Electrophorus electricus
(eel)) showed that the inhibition was reversible competitive (see
Supporting information), and considering the structural analogy with
the other inhibitors, compounds (rac)-2 to (rac)-4, would be expected to
be also competitive inhibitors.
Although the inhibition of eeAChE by (rac)-1 was shown to be weak
(500 μM), considering the inherent genomic sequence difference be-
tween both eeAChE and hAChE and eqBuChE and hBuChE16 it was of
interest to conduct some docking studies to gain some insights on the
type of binding interactions between the ligand and the enzyme. It
should be noted that the docking studies were conducted with both
enantiopodes of (rac)-1.
We used the PDB structures 4EY7 (human AChE) and 4TPK (human
BuChE) for our docking studies.
In the case of our docking studies with AChE, it was observed that
compound (S)-1 established a H-bond interaction between a hydrogen
atom of the ligand’s piperidine’s protonated amine and Glu202, at a
distance of 1.94 Å, a H-π interaction between the piperidine ring po-
sition 4 hydrogen atom and Trp86, at a distance of 3.09 Å, a second H-π
between the 3-hydroxy group and Phe338, at a distance of 2.89 Å and a
π-π interaction between the 3-phenyl group and Tyr341 at a distance of
3.11 Å (Fig. 3).
Compound (R)-1 establishes two H-bonds, one between the 3-hy-
droxy group and Asp74, at a distance of 1.94 Å, and a second, weaker
H-π interaction between the 3-phenyl group and Asp74, at a distance of
2.14 Å (Fig. 3). The ligand also establishes two H-π interactions, one
between the piperidine ring’s protonated amine and Trp86, at a dis-
tance of 2.98 Å and a second one between one of the piperidine ring
methylene bridge’s hydrogen atoms and Phe338, at a distance of 3.34 Å
(Fig. 4). A π-π interaction (hydrophobic interaction) is also established
between the ligand’s core aromatic ring and Tyr341, at a distance of
3.87 Å. Finally, an intramolecular (ligand-ligand) strong H-bond is es-
tablished between the 2-carbonyl group and one of the piperidine ring's
axial hydrogen atoms, locking the piperidine ring in the chair con-
formation (Fig. 3).
The set of interactions of compound (R)-1 with AChE are translated
to a ChemPLP scoring function value of 74.4, which was higher than
that of its enantiopode, thus indicating that in the case of the assays
with (rac)-1, it would be this enantiomer that is the strongest binder of
the two. To correlate the stability and interaction patterns of Donepezil
inside the hAche binding site with (rac)-1 it was calculated and com-
pared with both enantiomers of 1 (it should be noted that Donepezil is
prescribed as the racemate, but in these studies we used the (R)-en-
antiomer). These studies revealed that the Donepezil binds exactly in
the same region of the AChE binding site as that of (S)-1 and (R)-1,
undergoing hydrophobic interactions with Trp86 (π-π interaction), and
Trp286 (π-π interaction), and with Phe295 via a hydrogen bond with
the carboxylic oxygen (Fig. 3F). Again, the presence of hydrophobic
interactions with Trp86 is essential for the inhibitory activity.
It should be noted that we have previously conducted docking
studies with (rac)-2 using crystal structures of human AChE at 2.35 Å
(PDB code 4EY7) and human BuChE at 2.10 Å (PDB code 4BDS),10 and
the results showed that Trp86 manifested a hydrophobic interaction
with the oxindole group and Phe338 showed a key hydrophobic in-
teraction with the benzyl group, which was expected in this case.
2.2.2. Ligand interactions with butyrylcholinesterase
Kinetic studies using (rac)-1 and eqBuChE (equine) showed that the
inhibition was reversible competitive (see Supporting information), and
considering the structural analogy with the other compounds, in-
hibitors (rac)-2 to (rac)-4, would be expected to be also competitive
inhibitors. In fact, the Ki was determined to have a value of
41 ± 12 µM.
Compound (S)-1 establishes a H-bond between the piperidine ring
protonated amine group and Gly116, at a distance of 2.11 Å, a π-π in-
teraction between the 3-phenyl group and Trp82, at a distance of 3.74 Å
and a second π-π interaction between the ligand’s core aromatic ring
and Tyr332, at a distance of 3.51 Å (Fig. 4).
Compound (R)-1 establishes a H-bond between piperidine’s proto-
nated amine and Pro285, at a distance of 1.87 Å, a second H-bond be-
tween the 3-hydroxy group and His438, at a distance of 1.95 Å, an H-π
interaction between the piperidine ring methylene bridge’s hydrogen
atom and the Phe329 amino acid residue, at a distance of 3.09 Å and a
π-π interaction between the 3-phenyl group and Trp82 at a distance of
3.30 Å (Fig. 4). The set of interactions simulated here were different
from those that were simulated previously for (rac)-2, which was
probably due to the presence of the benzyl group in (rac)-2.
The set of interactions of compound (R)-1 with BuChE presented a
ChemPLP scoring function value of 60.36. In this case, contrary to
AChE, it is (S)-1 that is the better binder. This difference is the result of
dissimilarities in the structure of the surface of the ChE active site, the
more hydrophobic nature of the BuChE active site surface favors the S-
enantiomer, whereas, the more aliphatic surface of the AChE active site
favors the R-enantiomer.
2.3. STD-NMR study of the AChE- (rac)-1 interaction
STD-NMR is a well-known physico-chemical technique that allows
one to study protein-ligand interactions in a quantitative manner, it
allows one to deduce the proximity of key regions (including functional
groups) of the ligand with the protein active site.17,18 (rac)-1 was used
for this study.
This method was used to validate the results obtained in the mo-
lecular docking studies discussed above. In the case of AChE (eel) the
following results were obtained (Fig. 5). H19 presented a 100% at-
tenuation and the piperidine ring a 65% STD- attenuation, probably due
to CH-π interaction with Trp86. This was previously simulated in the
case of (R)-1 with a predicted bond distance of 2.98 Å between the
piperidine ring’s protonated amine and Trp86. The phenyl ring showed
a 47%-59% attenuation, probably due to π-π stacking with Tyr 341 as
was simulated above in the case of (S)-1. The fused benzene ring of the
oxindole core, showed attenuations in the range 55–59%, which sup-
ports a π-π interaction between this unit and Tyr341 in the case of the
(R)-enantiomer.
Very different results were obtained, upon conducting the same
study with BuChE (see Fig. 6). The phenyl group protons presented an
STD-attenuation of 74%-100%, probably due to π-π stacking with
Trp82 as was simulated for both (S)-1 and (R)-1. In the case of the fused
benzene protons of the oxindole core an STD-attenuation of between
79% and 100% was observed, which supports π-π stacking with Tyr332
in the case of (S)-1 (Fig. 6).
It should be noted that a very similar result has previously been
observed for the STD-NMR study of (rac)-3 with eqBuChE, the fused
benzene oxindole ring presented attenuations in the range 55–100%,
the methylene unit of the benzyl group an attenuation of 20%, and the
3-phenyl ring assumed an attenuation of 125%, thus further validating
this study.
Our STD results would seem to indicate that the interactions be-
tween (rac)-1 and BuChE are stronger than with AChE, suggesting a
better level of inhibition of BuChE than AChE, which was found to be
indeed the case (the IC50 was 18.26 μM).
2.4. Brine shrimp toxicity evaluation
Results show that (rac)-1 presented 5% of mortality at a con-
centration of 1000 µg mL−1 (3.10 mM) and the commercial standard,
donepezil, presented 26% mortality for 1000 µg mL−1 (2.64 mM). No
mortality was observed with the negative controls, with and without
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DMSO and when potassium dichromate (K2Cr2O7) was used as a posi-
tive control, with a concentration of 100 µg mL−1 (0.34 mM) the mor-
tality rose to 100%. The dose-response curve for potassium dichromate
showed an LC50 value of 15.04 µg mL−1 (0.05 mM). On the other hand
(rac)-1 presented a mortality of only 5% lethality at a concentration of
3.10 mM as opposed to a mortality of 26% at a 2.64 mM concentration
in the case of donepezil.
2.5. Acute toxicity evaluation of cholinesterase inhibitors
Acute toxicity of (rac)-1 was evaluated in swiss albino mice and the
LD50 was determined according to the Up and Down procedure.19 The
estimated LD50 was aprox. 100 mg kg−1. The LD50 of donepezil for in-
travenous administration reported in the literature was 3.7 mg kg−1.20
On comparing these results, (rac)-1 presented an LD50 higher than
donepezil, suggesting that our compound is less toxic than donepezil.
2.6. Ex vivo pharmacological evaluation
The activity of AChE in the brain was measured in the presence of
donepezil hydrochloride, that showed an IC50 of 1.06 ± 0.29 µM
(Fig. 7) and in the presence of (rac)-1, which gave 28% inhibition at the
Fig. 3. Compound (S)-1 (green) interaction with hAChE (PDB 4EY7) residues in the binding pocket. (A) Binding mode and residues interacting in the binding pocket
and (B) Interactions diagram; Compound (R)-1 (violet) interaction with hAChE (PDB 4EY7). (C) Binding mode and residues interacting in the binding pocket and (D)
Interactions diagram, (E) Superimposed poses of compounds (S)-1 and (R)-1; (F) Superimposed poses of compounds (S)-1, (R)-1, and donepezil (cyan) (generated
with MOE 2016.08 and PyMol). The key binding site residues are displayed.
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highest concentration tested (1.5 mM). Donepezil had the lower IC50.
(rac)-1 and donepezil were also tested in the mouse liver (Figs. 8
and 9). Donepezil showed no selectivity, inhibiting both enzymes, AChE
and BuChE with IC50 values of 125.31 ± 1.19 and 147.23 ± 1.16 µM,
respectively.
(rac)-1 was also tested for AChE and BuChE inhibition (Fig. 9) and it
proved to be a better inhibitor of BuChE than of AChE. However, by
comparing these results with those obtained for donepezil in Fig. 8, we
realized that (rac)-1 showed higher IC50 values with either AChE or
BuChE.
In terms of pharmacokinetics, donepezil is metabolized by CYP 450
isoenzymes 2D6 and 3A4 and is excreted intact in the urine and ex-
tensively metabolized to four major metabolites, two of which are
known to be active, as well as a number of minor metabolites, not all of
which have been identified. Due to the similarity of our compound
structure with that of donepezil it is possible that (rac)-1 has a similar
Fig. 4. Compound (S)-1 (green) interaction with hBuChE (PDB 4TPK) residues in the binding pocket. (A) Binding mode and residues interacting in the binding pocket
and (B) Interactions diagram; Compound (R)-1 (violet) interaction with hBuChE (PDB 4TPK). (C) Binding mode and residues interacting in the binding pocket and (D)
Interactions diagram; (generated with MOE 2016.08 and PyMol). The key binding site residues are displayed.
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pharmacokinetic profile to donepezil.21
2.7. In vivo pharmacological evaluation
Both donepezil hydrochloride and (rac)-1 decreased AChE activity
in the brain, with values significantly different from the control
(p < 0.05) (Fig. 10). Interestingly, (rac)-1 presented a better AChE
inhibition than donepezil, although the results were not significantly
different (p > 0.05). AChE activity in the brain of swiss mice after the
administration of 3 mg/Kg of (rac)-1 was 0.096 µmol.min−1.mg−1
while for donepezil it was 0.112 µmol.min−1.mg−1.
Donepezil is a selective, reversible and noncompetitive inhibitor of
AChE in vitro and relatively selective for brain AChE in vivo.22
It was possible to determine both AChE and BuChE activity in the
liver (Fig. 11). Donepezil and (rac)-1 didn’t present significantly dif-
ferent values to each other, suggesting no relevant inhibition of both
cholinesterases in the liver. On the other hand, the 3 mg kg−1 admin-
istration of both donepezil and (rac)-1 presented the same level of in-
hibition for liver BuChE. As the molecular weight of donepezil
(415.96 g/mol) is similar to the molecular weight of (rac)-1 (358.87 g/
mol), the same doses of both compounds are almost equivalent to
equimolar doses. At the same time, by measuring the corresponding
brain AChE inhibition level we could obtain crucial information on the
comparison of the effect of (rac)-1 on AChE with that of the standard
donepezil. The two concentrations of (rac)-1 tested decreased AChE
activity in the brain by the same percentage, showing no overall ben-
efits in the administration of a dose higher than 3 mg kg−1. With re-
gards to BuChE activity in the brain, no useful results were obtained
since it was not possible to quantify this enzyme’s activity in the brain
of our healthy mouse model.23,24
3. Conclusions
The overall aim of this study was to determine the pharmacological
properties of (rac)-1 in a mouse model and determine its potential for
use as an alternative ChE inhibitor for the treatment of AD.
(rac)-1 was chosen due to its favorable water solubility properties
compared to analogues with better enzyme binding values. Preliminary
molecular docking studies were conducted with both (R) and (S)-1 with
hAChE and hBuChE, prior to advancing to the mouse model, and indeed
favorable interactions were observed, with (R)-1 showing the best
binding with AChE and (S)-1 with BuChE. STD-NMR studies were used
to successfully validate these results.
Both (rac)-1 and donepezil presented low toxicity against Artemia
salina (LC50 > 1000 µg mL−1), with (rac)-1 being the less toxic of the
two.
Gratifyingly it was found that (rac)-1 presented a slightly better
inhibition of AChE than donepezil in the mouse brain and the same
level of inhibition for mouse liver BuChE as donepezil.
4. Experimental section
4.1. Chemicals
All reagents were obtained from Sigma-Aldrich. rac-4-((3-hydroxy-
2-oxo-3-phenylindolin-1-yl) methyl) piperidin-1-ium chloride was syn-
thesized as previously described.10 AChE used in the STD-NMR assays
was from Electrophorus eletricus (VI-S lyophilized powder, 814 U mg−1
protein), BuChE used in the STD-NMR assays was from equine serum
(lyophilized powder, 1830 U mg−1 protein). The lyophilized enzymes
were prepared in 20 mM Tris-HCl D2O pH 7.6 buffer. Donepezil hy-
drochloride solution was prepared in DMSO-d6 and (rac)-1 solution was
Fig. 5. STD-NMR spectra for (rac)-1 performed at 400 MHz, 15 °C, and 3 s saturation time. (A) Reference spectrum. (B) STD spectrum of (rac)-1 (0.8 mM) with AChE
(4 μM). Binding epitope of (rac)-1 from the STD NMR experiment. The numerical values for the binding epitope of (rac)-1 designate the fraction of saturation as a
percentage, between the ligand protons and the protein active site, normalized to the maximum ligand STD attenuated signal (H19; 100%).
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prepared in D2O to the desired concentrations. Compounds used in the
A. salina assay were prepared in a saline solution. Compounds used in
the animal acute toxicity assay, were prepared in distilled water.
Compounds used in the in vivo animal assay were prepared in distilled
water and in the ex vivo animal assay were prepared in phosphate
buffer.
4.2. Synthesis of (rac)-1
This compound was synthesized according to our previous
method.10
1H NMR (DMSO-d6, 400 MHz) 1H NMR (CDCl3, 400MHz) δ: 9.00
(sbroad, 1H), 8.75 (sbroad, 1H), 7.37 – 7.25 (m, 5H), 7.16 (t, 2H,
J= 7.3Hz), 7.05 (t, 1H, J= 7.4Hz), 6.75 (s, 1H), 3.66 – 3.53 (m, 2H),
3.26 – 3.20 (m, 2H), 2.82 – 2.79 (m, 2H), 2.10 – 2.05 (m, 1H), 1.85 –
1.72 (m, 2H), 1.49 – 1.35 (m, 2H) ppm.
13C NMR (DMSO-d6, 400 MHz) δ: 177.1, 142.9, 141.3, 133.1, 129.4,
128.2, 127.6, 125.5, 124.6, 122.8, 109.3, 76.9, 44.2, 42.6, 42.5, 31.9,
26.2, 26.1 ppm.
4.3. Docking studies
Docking studies were conducted by designing both enantiomers of
compound 1, namely (S)-1 and (R)-1. Both the enantiomers were stu-
died in their protonated forms, due to the physiological pH of the cell.
The structures of these compounds were built, and their energy mini-
mized using the MMF94x forcefield, within the Molecular Operating
Environment (MOE) version 2016.0814. To prepare the enzymes for the
molecular docking studies, the co-crystallized inhibitors as well as all
the crystallographic waters included in the PDB structure, were re-
moved. Hydrogen atoms were then added and the protonation states
were correctly assigned using the Protonate-3D tool within the Mole-
cular Operating Environment (MOE) 2016.08 software package.
The molecular docking simulations were performed, using GOLD
software version 5.2.025 and carried out in the PDB structures 4EY7
(human AChE)26 and 4TPK (human BuChE)27 downloaded from Protein
Data Bank.
For each compound, 1000 docking runs were performed. Each
conformation was ranked according to its scores, GoldScore scoring
function scores were rescored with ChemPLP scoring function. For each
ligand structure, the top 3 solutions were visually inspected and criti-
cally evaluated. For both structures (4EY7 and 4TPK) the docking
protocol (number of runs, binding site center, presence of waters in the
active site, radius) were validated using the crystallographic ligands
and their poses were able to reproduce the positions of the respective
Fig. 6. STD-NMR spectra for (rac)-1 performed at 400 MHz, 15 °C, and 3 s saturation time. (A) Reference spectrum, (B) STD spectrum of (rac)-1 (0.8 mM) with BuChE
enzyme (4 μM). Binding epitope of (rac)-1 from the STD-NMR experiment. The numerical values for the binding epitope of (rac)-1 designate the saturation as a
percentage, between the ligand protons and the protein active site, normalized to the maximum ligand STD signal (H2, H14, H16; 100%).
Fig. 7. Dose-response relation of AChE in the brain of Swiss mice in the pre-
sence of donepezil.
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crystallographic ligands with a root-mean-square deviation (RMSD)
lower than 1 Å.
4.4. STD-NMR experiments
The NMR spectroscopy experiments were performed on a Bruker
Avance III 400 MHz spectrometer equipped with a 5 mm broadband
(PABBO BB/19F-1H/D Z-GRD) resonance probe head. STD NMR ex-
periments were carried out with solvent suppression and a 10 ms spin-
lock filter after the 90° pulse to reduce residual signals from the protein.
For selective saturation, cascades of Gaussian pulses with a length of
50 ms and 40–60 dB of attenuation were employed, with an interpulse
delay of 1 ms.28,29 The on-resonance and off-resonance frequencies
were set to 0 and 12000 Hz, respectively. STD-NMR controls were
performed using the ligand itself. Blank experiments were performed to
guarantee the absence of direct saturation of the ligand proton signals.
The relaxation delay was properly adjusted so that the experiment time
length was kept constant at 6.5 s. Water suppression at 1880 Hz
(4.7 ppm) was conducted. A sweep-width of 8012.82 Hz (20.03 ppm)
was employed. Specifically, the saturation time to obtain the STD
buildup curves were recorded at 0.25, 0.5, 1, 2, 3, 4, and 5 s.17,18
A 5 μM eqBuChE (equine) or eeAChE (Electrophorus electricus (eel))
solution was prepared in a Tris-HCl buffer in 99.9% D2O (20 mM at pH
7.4). A 5 mM stock solution was prepared for each compound (ligand).
Samples for NMR analysis were prepared by adding 100 μL of the ligand
to a 500 μL of enzyme solution.
4.5. Brine shrimp toxicity assay
The toxicity of standard and sample solutions was evaluated using
the A. salina L. lethality bioassay in order to determine the lethal
concentration that correspond to 50% dead larvae (LC50).30 The pro-
cedure was performed according to the Artoxkit M protocol (Micro-
BioTests, Inc.)31 In a multiwell test plate, 100 µL of each solution was
added to 900 µL of a saline medium and 10 larvae were added to each
well. Assays were repeated nine times for each concentration. Plates
were observed after 24 h of incubation, at 25 °C, using a Research
Stereomicroscope System (Olympus SZX9) and dead nauplii counted.
LC50 values were determined using GraphPad Prism 5TM software. Po-
tassium dichromate was used as a positive control (3.125 µg mL−1 to
150 µg mL−1). Two negative controls were prepared with a saline
medium without DMSO and with 5% DMSO.
Fig. 8. Dose-response relation of (A) AChE and (B) BuChE in the liver of Swiss mice, in the presence of donepezil.
Fig. 9. Dose-response relation of AChE and BuChE in the liver of swiss mice, in the presence of (rac)-1.
Fig. 10. In vivo AChE activity in the brain of swiss mice, in the presence of
donepezil and (rac)-1. Different letters represent values significantly different
(p < 0.05).
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4.6. Animals
The acute toxicity study and the pharmacological evaluation were
carried out using 8 weeks old male Swiss albino mice (Mus musculus),
weighting 23 ± 1 g. The organs (brain and liver) used to determine the
IC50 values were obtained from Swiss mice. All animals were housed in
a controlled environment (12 h light/dark cycles, 23 ± 1 °C) with food
and water ad libitum. Food was withheld 16 h before the experiments.
Procedures were conducted in accordance with the National Institutes
of Health Guide for Care and Use of Laboratory Animals Guidelines and
European Community Guidelines.32 All procedures involving animals
were approved by the Ethics Committee.33
4.7. Preparation of animals
4.7.1. Acute intraperitoneal toxicity evaluation
Acute toxicity of (rac)–1 was evaluated in swiss albino mice and the
LD50 was determined according to the OECD Up-and-Down procedure.19
The animals were divided into two groups of 3 mice each. The
compound administration was by intraperitoneal (i.p.) injection in the
upper left quadrant of the animal’s abdomen. The animals were kept in
observation for 15 days, during which they were housed in a controlled
environment (12 h light/dark cycles, 23 ± 1 °C) with food and water
ad libitum.
4.7.2. Ex vivo pharmacological evaluation
Animals were sacrificed by decapitation, and brains and livers were
dissected out, washed in ice-cold potassium phosphate buffer (0.2 M,
pH 7.6), and homogenized. The brain homogenate was prepared in
potassium phosphate buffer 0.1 M, pH 7.6 (1:10, w/v), and then cen-
trifuged at 10,000 g and 4 °C for 10 min. The liver homogenate was
prepared in potassium phosphate buffer 0.1 M, pH 7.6 (1:10, w/v), and
then centrifuged at 1000 g and 4 °C for 15 min.
Donepezil hydrochloride and (rac)-1 were prepared in potassium
phosphate buffer (0.2 M, pH 7.6), and were tested against AChE activity
in the brain and both AChE and BuChE activity in the liver.
AChE and BuChE activity was determined following a modified
Ellman’s method,34 and the IC50 values were calculated.
Total protein quantification followed the Lowry method.35
4.7.3. In vivo pharmacological evaluation
The animals were divided into four groups of six animals. The
compounds administration was by intraperitoneal (i.p.) injection in the
upper left quadrant of the animal’s abdomen. Group I was administered
with the vehicle (distilled water), group II was administered with
3 mg kg−1 of donepezil hydrochloride, group III was administered with
3 mg kg−1 of (rac)-1 and group IV was administered with 6 mg kg−1 of
(rac)-1.
Animals were sacrificed by decapitation, 1 h after i.p. injection, and
brains and livers were dissected out, washed in ice-cold potassium
phosphate buffer (0.2 M, pH 7.6), and homogenized. The brain homo-
genate was prepared in potassium phosphate buffer 0.1 M, pH 7.6
(1:10, w/v), and then centrifuged at 10,000 g and 4 °C for 10 min. The
liver homogenate was prepared in potassium phosphate buffer 0.1 M,
pH 7.6 (1:10, w/v), and then centrifuged at 1000 g and 4 °C for 15 min.
AChE and BuChE activities were determined following a modified
Ellman’s method,34 and the IC50 values were calculated.
Total protein quantification followed the Lowry method.35
4.8. Statistical analysis
All data was expressed as mean ± standard deviation of triplicate
measurements. Statistical analysis of data was performed using one-
way ANOVA. A probability value of p < 0.05 was considered statisti-
cally significant. Multiple comparisons of means were analyzed using
the b-Tukey test. Analyses were performed using SPSS® 22 Windows,
IBM. The dose-response curve and the LC50 values, as well as the IC50
for all the samples were determined with the software GraphPad Prism
5™.
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